X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA LUPIN LTD NATCO PHARMA/
LUPIN LTD
 
P/E (TTM) x 23.4 20.1 116.8% View Chart
P/BV x 17.7 2.7 652.9% View Chart
Dividend Yield % 0.6 0.9 69.9%  

Financials

 NATCO PHARMA   LUPIN LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
LUPIN LTD
Mar-17
NATCO PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs8771,750 50.1%   
Low Rs4241,384 30.6%   
Sales per share (Unadj.) Rs223.4387.4 57.7%  
Earnings per share (Unadj.) Rs31.156.6 54.9%  
Cash flow per share (Unadj.) Rs40.376.8 52.4%  
Dividends per share (Unadj.) Rs5.007.50 66.7%  
Dividend yield (eoy) %0.80.5 160.6%  
Book value per share (Unadj.) Rs219.5298.9 73.4%  
Shares outstanding (eoy) m33.07451.58 7.3%   
Bonus/Rights/Conversions PAESOPS-  
Price / Sales ratio x2.94.0 72.0%   
Avg P/E ratio x20.927.7 75.7%  
P/CF ratio (eoy) x16.120.4 79.2%  
Price / Book Value ratio x3.05.2 56.5%  
Dividend payout %16.113.2 121.5%   
Avg Mkt Cap Rs m21,504707,513 3.0%   
No. of employees `000NA16.8 0.0%   
Total wages/salary Rs m1,12828,495 4.0%   
Avg. sales/employee Rs ThNM10,418.3-  
Avg. wages/employee Rs ThNM1,697.0-  
Avg. net profit/employee Rs ThNM1,523.0-  
INCOME DATA
Net Sales Rs m7,389174,943 4.2%  
Other income Rs m1671,065 15.7%   
Total revenues Rs m7,556176,008 4.3%   
Gross profit Rs m1,79344,931 4.0%  
Depreciation Rs m3049,122 3.3%   
Interest Rs m3661,525 24.0%   
Profit before tax Rs m1,29035,349 3.6%   
Minority Interest Rs m46-72 -64.6%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3099,785 3.2%   
Profit after tax Rs m1,02725,575 4.0%  
Gross profit margin %24.325.7 94.5%  
Effective tax rate %23.927.7 86.5%   
Net profit margin %13.914.6 95.1%  
BALANCE SHEET DATA
Current assets Rs m3,681119,542 3.1%   
Current liabilities Rs m3,12361,206 5.1%   
Net working cap to sales %7.633.3 22.7%  
Current ratio x1.22.0 60.4%  
Inventory Days Days8976 117.7%  
Debtors Days Days5990 65.3%  
Net fixed assets Rs m7,685131,660 5.8%   
Share capital Rs m331903 36.6%   
"Free" reserves Rs m6,670134,073 5.0%   
Net worth Rs m7,259134,976 5.4%   
Long term debt Rs m95556,478 1.7%   
Total assets Rs m11,957266,073 4.5%  
Interest coverage x4.524.2 18.7%   
Debt to equity ratio x0.10.4 31.4%  
Sales to assets ratio x0.60.7 94.0%   
Return on assets %11.710.2 114.4%  
Return on equity %14.218.9 74.7%  
Return on capital %20.719.3 107.6%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44581,885 4.2%   
Fx outflow Rs m70321,506 3.3%   
Net fx Rs m2,74360,378 4.5%   
CASH FLOW
From Operations Rs m1,44041,148 3.5%  
From Investments Rs m-1,089-25,287 4.3%  
From Financial Activity Rs m-3534,332 -8.1%  
Net Cashflow Rs m-120,193 -0.0%  

Share Holding

Indian Promoters % 52.0 46.6 111.7%  
Foreign collaborators % 1.5 0.2 735.0%  
Indian inst/Mut Fund % 7.8 11.3 69.4%  
FIIs % 16.6 31.9 52.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.1 257.4%  
Shareholders   25,395 98,259 25.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   IPCA LABS  NOVARTIS  PLETHICO PHARMA  MERCK LTD  SANOFI INDIA  

Compare NATCO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 21, 2018 03:35 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS